CXD101 是一种有效的，选择性的，具有口服活性的 I 类 HDAC 抑制剂，对 HDAC1，HDAC2 和 HDAC3 的 IC50 分别为 63 nM，570 nM 和 550 nM。CXD101 对 II 类 HDAC 没有活性，并具有抗肿瘤活性。

UNC3866 是一种有效的 CBX7-H3 拮抗剂，IC50 为 66±1.2 nM。

I-CBP112是一种特异性和有效的乙酰-赖氨酸竞争性蛋白-蛋白相互作用抑制剂，抑制 CBP/p300 溴结构域，增强 p300 的乙酰化作用。

OICR-9429是一个新颖的相互作用的小分子Wdr5-MLL拮抗剂，IC50是5 uM，能够抑制增殖。

CeMMEC13 是一种有效的 TAF1 (2) 抑制剂，IC50 值为 2.1 μM。

Fimepinostat (CUDC-907) 有效抑制 I 型 PI3K 及 I 和 II 型 HDAC 酶，作用于 PI3Kα/PI3Kβ/PI3Kδ 和 HDAC1/HDAC2/HDAC3/HDAC10 ，IC50 分别为 19/54/39 nM 和 1.7/5.0/1.8/2.8 nM。

Vafidemstat (ORY-2001) 是一种双重的赖氨酸特异性组蛋白去甲基化酶 (LSD1)/MAO-B 抑制剂。

Inauhzin 是 SirT1/IMPDH2 的双重抑制剂，同时为 p53 的激活剂，可用于癌症研究。

Tubacin is a selective inhibitor of HDAC6 via inhibition of the second deacetylase domain (DD2).

OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 1/2.

Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM; >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2.

SIRT2 Inhibitor II, AK-1 inhibits SIRT2 selectively over SIRT1 and SIRT3.

CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.

SP2509 is a novel histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM; no inhibition on MAO-A and MAO-B.

The (-)-JQ1 stereoisomer has no appreciable affinity to BET bromodomains，it is the negative control of +JQ-1.

AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 uM) with potential anticancer activity, >600 fold than SMYD3(IC50>83.3 uM); DOT1L(IC50>83.3 uM);EZH2(IC50>83.3 uM).

GSK1324726A In stock,price: 680 USD/100mg. GSK1324726A (I-BET726) is a novel, potent, and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50= 41 nM), BRD3 (IC50= 31 nM), and BRD4 (IC50= 22 nM).

SRT1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 μM；SIRT3: EC1.5 > 300 μM).

SRT3025 is a sirt1 activator.

Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively.